Clinical trials: Cancer, Carcinoma
Oral Squamous Cell Carcinoma
Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma
Up to 31 subjects diagnosed with oral squamous cell carcinoma received one application of a permeation enhancer 3 treatment applications of a Cisplatin drug-loaded patch to the tumor site at each of the 4 treatment visits.
- Trial name
- PRV111 (NCT03502148)
- Testing
- PRV111 (Cisplatin Transmucosal System)
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Privo Technologies
Non-Small-Cell Lung Carcinoma
Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer
Phase II, randomised, controlled, non comparative study with 2 parallel groups: Arm A: patients will receive induction chemotherapy (cisplatin and docetaxel) followed by a concomitant radio-chemotherapy including 2 cycles of…
- Trial name
- NCT00985855
- Testing
- cisplatin, vinorlebine, cetuximab, cisplatine, etoposide, cetuximab
- Where
- France
- Volunteers
- 91 people
- Sponsor
- Institut de Cancérologie de la Loire
Carcinomas, Disease, Hodgkin
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
The purpose of this study is to identify brentuximab vedotin drug-drug interactions in patients with CD30-positive cancers and to determine the main route of excretion.
- Conditions
- Carcinomas, Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
- Trial name
- NCT01026415
- Testing
- brentuximab vedotin, rifampin, midazolam
- Where
- 6 sites in United States
- Volunteers
- 73 people
- Sponsor
- Seagen Inc.
Non-Small Cell Lung Cancer
Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR
A Phase III, multicenter, open-label, randomized trial of Erlotinib (Tarceva®) versus chemotherapy in patients with advanced NSCLC with mutations in the Tyrosine Kinase (TK) domain of the EGFR.
- Trial name
- EURTAC (NCT00446225)
- Testing
- Erlotinib, Carboplatin, Gemcitabin
- Where
- 76 sites in France, Italy and 1 more
- Volunteers
- 174 people
- Sponsor
- Spanish Lung Cancer Group
Carcinoma, Non-Small-Cell-Lung
Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer
The purpose of this study is to evaluate the safety of I-PDT with Temoporfin for patients with Non-Resectable Non-Small-Cell Lung Cancer (NR-NSCLC).
- Trial name
- NCT01637376
- Testing
- Temoporfin
- Where
- United States
- Sponsor
- University of Arkansas
Non-Small Cell Lung Cancer
Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
This is a Phase 3 Randomized, double-blind, Multicenter Study of Ivonescimab Combined with Docetaxel Versus Placebo Combined with Docetaxel in Patients with Locally advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) that…
- Trial name
- NSCLC (NCT06928389)
- Testing
- Ivonescimab, docetaxel
- Where
- China
- Volunteers
- 536 people
- Sponsor
- Akeso
Lung Cancer, Nonsmall Cell
Plasmodium Immunotherapy for Lung Cancer
The objective of this study is to evaluate the safety and the effectiveness of Plasmodium immunotherapy (blood-stage infection of Plasmodium vivax) for advanced non-small cell lung cancer.The treatment will last 3-6 months from…
- Trial name
- NCT02786589
- Testing
- Blood-stage infection of P. vivax
- Where
- China
- Volunteers
- 30 people
- Sponsor
- State Key Laboratory of Respiratory Disease
Esophageal Cancer, Gastrointestinal Complications
Plastic Stents Compared With Metal Stents in Treating Patients With Malignant Dysphagia Caused by Esophageal Cancer or Gastroesophageal Junction Cancer
RATIONALE: Placing a stent in the esophagus may lessen swallowing difficulties and improve quality of life in patients with malignant dysphagia caused by esophageal cancer or gastroesophageal junction cancer.
- Trial name
- NCT00372450
- Testing
- management of therapy complications, quality-of-life assessment
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Thyroid Cancer
Comparison of Quality of Life in Patients with Differentiated Thyroid Carcinoma Undergoing Different Surgery
The incidence of thyroid cancer has increased rapidly in recent years, especially in women. Early differentiated thyroid cancer has a good prognosis, and surgery is the main treatment.
- Trial name
- NCT06037174
- Testing
- minimally invasive procedure, Conventional Open Surgery
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer
Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy
Drugs used in chemotherapy, such as rebeccamycin analog, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
- Trial name
- NCT00084487
- Testing
- becatecarin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8
Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer
This phase Ib/II trial studies the best dose of carboplatin when given together with berzosertib, gemcitabine and pembrolizumab and to see how well it works in treating patients with stage IV squamous cell non-small cell lung…
- Trial name
- NCT04216316
- Testing
- Berzosertib, Biospecimen Collection, Carboplatin
- Where
- 34 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma
The purpose of this study is to compare the efficacy and safety of sitravatinib plus tislelizumab or placebo plus tislelizumab versus placebo.
- Trial name
- NCT05564338
- Testing
- Sitravatinib, Tislelizumab
- Sponsor
- BeiGene
Urothelial Carcinoma
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
The purpose of this study is to test the safety and effectiveness of immunotherapy (checkpoint inhibitor therapy) in advanced bladder cancer when given intermittently.
- Trial name
- NCT04322643
- Testing
- Pembrolizumab, Atezolizumab, Durvalumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Case Comprehensive Cancer Center
Hepatocellular Carcinoma by BCLC Stage
TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria
The purpose of this study is to evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with anti-VEGF (Bevacizumab Biosimilar) in patients with BCLC-B stage hepatocellular carcinoma beyond…
- Trial name
- B-TACE (NCT05883176)
- Testing
- Bevacizumab Biosimilar QL 1101
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Microwave Ablation
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
This study intends to evaluate the efficacy and safety of low-dose adjuvant donafenib after thermal ablation for early recurrent HCC within Milan criteria.
- Conditions
- Hepatocellular Carcinoma, Microwave Ablation, Donafenib, Recurrent Tumor
- Trial name
- NCT06609876
- Testing
- Thermal ablation, Donafenib
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Sun Yat-sen University
Hepatitis, Hepatocellular Carcinomas
Identification of Specific Modulation Frequencies in Hepatitis B Carriers With and Without Hepatocellular Carcinoma
The propose of this study is to identification of a group of specific amplitude-modulated frequencies of low intensity electromagnetic fields that is associated with biofeedback upon exposure to in patients with hepatitis B…
- Trial name
- THBC-HSL2 (NCT01641276)
- Testing
- Low intensity amplitude-moduled electromagnetic fields
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hospital Sirio-Libanes
Head and Neck Cancer, Carcinoma, Squamous Cell
Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer
The purpose of this study is to determine if combination Erlotinib, Cisplatin/Carboplatin, and Paclitaxel are effective first line treatment for metastatic, recurrent and persistent squamous cell carcinoma of the head and neck.
- Trial name
- NCT00448240
- Testing
- Erlotinib
- Volunteers
- 6 people
- Sponsor
- Henry Ford Health System
Metastatic Non Small Cell Lung Cancer
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer…
- Trial name
- TROPION-Lung08 (NCT05215340)
- Testing
- Datopotamab Deruxtecan, Pembrolizumab
- Where
- 234 sites in United States, Argentina and 26 more
- Volunteers
- 740 people
- Sponsor
- Daiichi Sankyo
Hedgehog Pathway, Smoothened
A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer
The purpose of this study is to determine the safety of BMS-833923 (XL139) in patients with advanced or metastatic cancers and determine the recommended phase 2 dose range and schedule
- Conditions
- Hedgehog Pathway, Smoothened, Basal Cell Carcinoma (BCC), Basal Cell Nevoid Syndrome (BCNS)
- Trial name
- NCT00670189
- Testing
- BMS-833923 (XL139)
- Where
- 3 sites in United States, Canada
- Volunteers
- 53 people
- Sponsor
- Bristol-Myers Squibb
Deafness, Kidney Diseases
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors
The von Hippel Lindau (VHL) gene has recently been identified as the genetic defect resulting in a syndrome of multiple neoplasias.
- Conditions
- Deafness, Kidney Diseases, Kidney Neoplasms, Neoplasms
- Trial name
- NCT00001668
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.